Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.36 Increased by +66.36% | -0.56 Increased by +35.71% |
| Apr 12, 24 | -2.12 Decreased by -10.70 K% | -1.14 Decreased by -85.96% |
| Dec 31, 23 | -2.12 Decreased by -430.00% | -1.14 Decreased by -85.96% |
| Nov 9, 23 | -0.81 Decreased by -912.50% | -1.01 Increased by +19.80% |
| Aug 10, 23 | -1.07 Decreased by -1.43 K% | -0.87 Decreased by -22.99% |
| May 11, 23 | 0.02 Increased by +118.18% | -0.08 Increased by +125.00% |
| Mar 31, 23 | -0.40 Decreased by -233.33% | -0.09 Decreased by -344.44% |
| Nov 10, 22 | -0.08 Increased by +46.67% | -0.11 Increased by +27.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 104.00 K Decreased by -77.54% | -4.53 M Increased by +45.64% | Decreased by -4.36 K% Decreased by -142.02% |
| Mar 31, 24 | 176.00 K Decreased by -40.74% | -9.13 M Increased by +79.86% | Decreased by -5.19 K% Increased by +66.02% |
| Dec 31, 23 | 314.00 K Increased by +14.60% | -15.99 M Increased by +64.44% | Decreased by -5.09 K% Increased by +68.97% |
| Sep 30, 23 | 429.00 K Increased by +540.30% | -6.49 M Increased by +31.30% | Decreased by -1.51 K% Increased by +89.27% |
| Jun 30, 23 | 463.00 K Increased by +95.36% | -8.33 M Decreased by -3.67% | Decreased by -1.80 K% Increased by +46.93% |
| Mar 31, 23 | 297.00 K Decreased by -21.84% | -45.34 M Decreased by -324.21% | Decreased by -15.26 K% Decreased by -442.76% |
| Dec 31, 22 | 274.00 K Decreased by -92.37% | -44.98 M Decreased by -25.34% | Decreased by -16.42 K% Decreased by -1.54 K% |
| Sep 30, 22 | 67.00 K Decreased by -93.19% | -9.45 M Increased by +31.56% | Decreased by -14.10 K% Decreased by -905.18% |